The Jensen Group participate in an Innobooster project with biotech Orfazyme to study mechanisms in Parkinsons disease
In a recently established InnoBooster collaboration, PhD student Nanna Møller Jensen from Poul Henning Jensen’s group is collaborating with the Copenhagen-based biotech company, Orphazyme, in a quest for the development of novel therapies against Parkinson’s disease (PD).
The focus will be on the role of the lysosomal enzyme glucocerebrosidase, which have been identified as risk factors for PD. In the collaboration, the Jensen Group bring their extensive knowledge of both in vitro and in vivo models of PD. In particular, the organotypic hippocampal slice culture model, which Nanna assisted in the development of during her Master studies, will be used in relation to transgenic mouse models and viral vector based gene delivery. For the two year project period, Nanna Møller Jensen is employed at Orphazyme and will work in the Jensen group at Dandrite but also participate in training with and at Orfazyme. The 2-year project is funded by the Danish Innovation Fund.